Thetis Pharmaceuticals LLC — SEC Form D Filing

Thetis Pharmaceuticals LLC filed an SEC Form D on October 13, 2026, reporting $560K raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
October 13, 2026
Amount reported
$560K
Round stage
Series B+
Industry
Biotechnology
Website
https://www.thetispharma.com/

What the company does

Securities: Debt. Exemption: Rule 506(b). Incorporated: CONNECTICUT

Problem

The company addresses inflammatory bowel disease (IBD), specifically moderate-to-severe ulcerative colitis, and solid tumors.

Solution

Thetis Pharmaceuticals is developing TP-317, an oral Resolvin E1 (RvE1) drug that activates BLT1 to restore and maintain tissue and immune homeostasis.

Verdict

This cleared because the drug's mechanism offered a novel approach to highly prevalent inflammatory diseases, appealing to investors seeking pipeline diversification in an established therapeutic area. Investors were implicitly betting on early-stage clinical differentiation based on a potentially superior safety and efficacy profile, not on a proven market-entry strategy. This limited upside by anchoring the valuation to clinical milestones rather than rapid commercial scaling, contrasting with platform plays that offer broader applicability.

Source: SEC EDGAR Form D filing